3-methoxytyramine has been researched along with Idiopathic Parkinson Disease in 11 studies
3-methoxytyramine: RN given refers to parent cpd
3-methoxytyramine : A monomethoxybenzene that is dopamine in which the hydroxy group at position 3 is replaced by a methoxy group. It is a metabolite of the neurotransmitter dopamine and considered a potential biomarker of pheochromocytomas and paragangliomas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| "Parkinson's disease is a multifactorial neurodegenerative disorder, characterized by a reduction of dopamine (DA) levels." | 1.40 | Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease. ( Conte, C; Ianni, F; Lisanti, A; Natalini, B; Sardella, R; Scorzoni, S, 2014) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| "L-3,4-Dihydroxyphenylalanine (L-DOPA) is a common and effective treatment for Parkinson's disease, but dyskinesia continues to be a serious adverse effect with chronic use." | 1.31 | Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. ( Akiyama, A; Nakazato, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chtioui, H | 1 |
| Sadowski, SM | 1 |
| Winzeler, B | 1 |
| Tschopp, O | 1 |
| Grouzmann, E | 1 |
| Abid, K | 1 |
| Eisenhofer, G | 1 |
| Brown, S | 1 |
| Peitzsch, M | 1 |
| Pelzel, D | 1 |
| Lattke, P | 1 |
| Glöckner, S | 1 |
| Stell, A | 1 |
| Prejbisz, A | 1 |
| Fassnacht, M | 1 |
| Beuschlein, F | 1 |
| Januszewicz, A | 1 |
| Siegert, G | 1 |
| Reichmann, H | 1 |
| Sardella, R | 1 |
| Scorzoni, S | 1 |
| Conte, C | 1 |
| Lisanti, A | 1 |
| Ianni, F | 1 |
| Natalini, B | 1 |
| Konieczny, J | 1 |
| Czarnecka, A | 1 |
| Kamińska, K | 1 |
| Lenda, T | 1 |
| Nowak, P | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Gluck, MR | 1 |
| Zeevalk, GD | 1 |
| Jiang, H | 1 |
| Jiang, Q | 1 |
| Liu, W | 1 |
| Feng, J | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Nakazato, T | 1 |
| Akiyama, A | 1 |
| Dalmaz, Y | 1 |
| Peyrin, L | 1 |
| Kish, SJ | 1 |
| Rajput, A | 1 |
| Gilbert, J | 1 |
| Rozdilsky, B | 1 |
| Chang, LJ | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 1 |
11 other studies available for 3-methoxytyramine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy?
Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Dopamine; Dopam | 2019 |
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Topics: Aged; Aged, 80 and over; Chromatography, Liquid; Dopamine; Epinephrine; Female; Humans; Levodopa; Ma | 2014 |
Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebral Cortex; Chromatography, High Pressure Liquid; Chro | 2014 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine | 2004 |
Parkin suppresses the expression of monoamine oxidases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; B-Lymphocytes; Binding Sites; Cell Line, Transformed; Cell | 2006 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Dopam | 2002 |
Specific ion-exchange chromatography and fluorimetric assay for urinary 3-O-methyldopamine.
Topics: Adrenal Gland Neoplasms; Animals; Chromatography, Ion Exchange; Dogs; Dopamine; Humans; Hydrogen-Ion | 1976 |
Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
Topics: Brain Chemistry; Corpus Striatum; Dopamine; Ethanolamines; gamma-Aminobutyric Acid; Glutamate Decarb | 1986 |